Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019)

Akebia Therapeutics (AKBA) has disclosed Short-Term Debt repayments for 1 consecutive years, with $15.0 million as the latest value for Q1 2019.

  • Quarterly Short-Term Debt repayments changed N/A to $15.0 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2019, changed N/A year-over-year, with the annual reading at $32.0 million for FY2023, 3.03% down from the prior year.
  • Short-Term Debt repayments for Q1 2019 was $15.0 million at Akebia Therapeutics.
  • The five-year high for Short-Term Debt repayments was $15.0 million in Q1 2019, with the low at $15.0 million in Q1 2019.